Skip to main content Accessibility help
×
Home

The Role of Complex Combination Therapy in the Treatment of Refractory Bipolar Illness

  • Robert M. Post (a1), Mark A. Frye (a1), Gabriele S. Leverich (a1) and Kirk D. Denicoff (a1)

Abstract

In this article, we present rationales for using complex combination therapy in treatment-refractory bipolar patients and discuss the agents available for use in this therapeutic approach. We review a case example of successful remission that was achievable only with complex combination therapy, and examine its theoretical implications. Practical approaches to devising the optimal complex combination treatment for individual patients are explained, and we look to the development of new methodologies and a more systematic database for decision making in the future.

Copyright

References

Hide All
1. Kraepelin, K. Manic-Depressive Insanity and Paranoia. Barclay, RM, trans: Robertson, GM, ed, Edinburgh, Scotland: ES Livingstone; 1921.
2. Post, RM. Transduction of psychosocial stress into the neurobiology of recurrent affective disorder. Am J Psychiatry. 1992;149:9991010.
3. Post, RM, Weiss, SRB. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdala-kindled seizures. Mol Neurobiol. 1996;13:3360.
4. Marangell, LB, George, MS, Callahan, AM, et al. Effects of intrathecal protirelin (thyrotropin-releasing hormone) in refractory depressed patients. Arch Gen Psychiatry. 1997;54:214222.
5. Callahan, AM, Frye, MA, Marangell, LB, et al. Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implication for therapeutics. Biol Psychiatry. 1997;41:264272.
6. Prange, AJ Jr, Lara, PP, Wilson, IC, Alltop, LB, Breese, GR. Effects of thyrotropin-releasing hormone in depression. Lancet. 1972;11:9991002.
7. Post, RM, Weiss, SRB. Endogenous biochemical abnormalities in affective illness: therapeutic vs pathogenic. Biol Psychiatry. 1992;32:469484.
8. Post, RM, Leverich, GS, Pazzaglia, PJ, et al. Lithium tolerance and discontinuation as pathways to refractoriness. In: Birch, NJ, Padgham, C, Hughes, MS, eds. Lithium in Medicine and Biology. Lancashire, UK: Marius Press; 1993;7184.
9. Post, RM, Leverich, GS, Rosoff, AS, Altshuler, LL. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol. l990;10:318327.
10. Weiss, SR, Clark, M, Rosen, JB, Smith, MA, Post, RM. Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Brain Res Rev. 1995;20:305325.
11. O'Gonnell, RA, Mayo, JA, Flatow, L, Cuthbertson, B, O'Brien, BE. Outcome of bipolar disorder on Long-term treatment with lithium. Br J Psychiatry. 1991;159:123129.
12. Sarantidis, D, Waters, B. Predictors of lithium prophylaxis effectiveness. Prog Neuropsychopharmacol. 1981;5:507510.
13. Denicoff, KD, Smith-Jackson, EE, Disney, ER, Ali, SO, Leverich, CS, Post, RM. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry. 1997;58:470478.
14. Post, RM, Ketter, TA, Pazzaglia, PJ, et al. Rational polypharmacy in the bipolar affective disorders. Epilepsy Res. 1996;(suppl 11):153180.
15. Gelenberg, AJ, Kane, JM, Keller, MB, et al. Comparison of standard and low serum levels of lithium for maintenance treatment of bipolar disorder. N Engl J Med. 1989;321:14891493.
16. Koukopoulos, A, Reginaldi, D, Minnai, G, Serra, G, Pani, L, Johnson, FN. The long term prophylaxis of affective disorders. Adv Biochem Psychopharmacol. 1995;49:127147.
17. Markar, HR, Mander, AJ. Efficacy of lithium prophylaxis in clinical practice. Br J Psychiatry. 1989;15:496500.
18. Vestergaard, P. Treatment and prevention of mania: a Scandinavian perspective. Neuropsychopharmacol. 1992;7:249260.
19. Gitlin, MJ, Swendsen, J, Heller, TL, Hammen, C. Relapse and impairment in bipolar disorder. Am J Psychiatry. 1995;152:16351640.
20. Kravitz, HM, Fawcett, J. Carbamazepine in the treatment of affective disorders. Med Sci Res. l987;15:l8.
21. Schaff, MR, Fawcett, J, Zajecka, JM. Divalproex sodium in the treatment of refractory affective disorders. J Clin Psychiatry. 1993;54:380384.
22. Post, RM, Ketter, TA, Denicoff, K. et al. The place of anticonvulsant therapy in bipolar illness. Psychopharmacology (Berl). 1996;128:115129.
23. Post, RM, Denicoff, KD, Frye, MA, Leverich, GS. Re-evaluating carbamazepine prophylaxis in bipolar disorder. Br J Psychiatry. 1997;170:202204.
24. Frye, MA. The increasing use of polypharmacy for refractory mood disorders: twenty-five years of study. APA New Research Program and Abstracts. 1996;151152. Abstract.
25. Post, RM, Uhde, TW, Roy-Byrne, PP, Joffe, RT. Antidepressant effects of carbamazepine. Am J Psychiatry. 1986;143:2934.
26. Post, RM, Uhde, TW, Roy-Byrne, PP, Joffe, RT. Correlates of antimanic response to carbamazepine. Psychiatry Res. 1987;21:7183.
27. Kramlinger, KG, Post, RM. The addition of lithium carbonate to carbamazepine: antidepressant efficacy in treatment-resistant depression. Arch Gen Psychiatry. l989;46:794800.
28. Semyak, MJ, Woods, SW. Chronic neuroleptic use in manic-depressive illness. Psychopharmacol Bull. 1993;29:375381.
29. Hunt, N, Silverstone, T. Tardive dyskinesia in bipolar affective disorder a catchment area study. Int Clin Psychopharmacol. 1991;6:4550.
30. Jeste, DV, Wyatt, RJ. Therapeutic strategies against tardive dyskinesia. Arch Gen Psychiatry. 1982;39:803816.
31. Glenthoj, B, Hemmingsen, R, Allerup, P, Bolwig, TG. Intermittent versus continuous neuroleptic treatment in a rat model. Eur J Pharmacol. 1990;190:275286.
32. Calabrese, JR, Kimmel, SE, Woyshville, MJ. et al. Clozapine for treatment-refractory mania. Am J Psychiatory l996;153:759764.
33. McElroy, SL, Dessain, EC, Pope, HG Jr, et al. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia. J Clin Psychiatry. 1991;52:411414.
34. Suppes, I, McElroy, SI, Gilbert, J, Dessain, EC, Cole, JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992;32:270280.
35. Kerwin, R, Taylor, D. New antipsychotics. A review of their current status and clinical potential. CNS Drugs. l996;6:7182.
36. Keek, PE Jr., Wilson, DR, Strakowski, SM, et al. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder, and psychotic mood disorders. J Clin Psychiatry. 1995;56:466470.
37. Tohen, M, Zarate, CA Jr., Centorrino, F, Hegarty, JI, Froeschl, M, Zarate, SB. Risperidone in the treatment of mania. J Clin Psychiatry. 1996;57:219253.
38. Gross, C, Kin, X, Gastpar, M. Trimipramine: pharmacological reevaluation and comparison with clozapine. Neuropharmacology. 1991;30:11591166.
39. Eikmeier, G, Berger, M, Lodemann, E, Muszynski, K, Kaumeier, S, Gastpar, M. Trimipramine—an atypical neuroleptic? Int Clin Psychopharmacol 1991;6:117153.
40. Pazzaglia, PJ, Post, RM, Ketter, TA, George, MS, Marangell, LB. Preliminary controlled trial of nimodipine in ultra-rapid cycling affective dysregulation. Psychiatry Res. 1993;49:257272.
41. Pazzaglia, PJ, Post, RM, Ketter, TA, et al.Nimodipine monotherapy and carbamazepine augmentation in patients with refractory recurrent affective illness. J. Clin Psychopharmacol. In press.
42. Dubovsky, SL. Calcium channel antagonists as novel agents for manic-depressive disorder. In: Schatzberg, AF, Nemeroff, CB, eds. Textbook of Psychopharmacology. Washington, DC: American Psychiatric Press; 1995;377388.
43. Pazzaglia, PJ, George, MS, Post, RM, Rubinow, DR, Davis, C. Nimodipine increases CSF somatostatin in affectively ill patients. Neuropsychopharmacol. l995;13:7583.
44. Ban, TA, Morey, L, Aguglia, E, et al. Nimodipine in the treatment of old age dementias. Prog Neuropsychopharmacol Biol Psychiatry. 1990;144:525551.
45. Calabrese, JR, Bowden, CL, McElroy, SL, et al.Lamotrigine in bipolar disorder: preliminary data. Syllabus and Proceedings Summary of the 150th American Psychiatric Association Meeting, May 17-22,1997. Abstract No 33B.
46. Berlant, JL. ADHD and bipolar disorder as predictors of clinical response to lamotrigine. Proceedings of the Second International Conference on Bipolar Disonler, 1997:7. Abstract.
47. Ferrier, IN, Potkins, D, Eccleston, D. Lamotrigine treatment in rapid cycling bipolar disorder (BPD): clinical and biological correlates. Proceedings of the Second International Conference on Bipolar Disonler. 1997;15. Abstract.
48. Hoopes, S, Snow, M. Clinical effectiveness of lamotrigine in affective disorders. Proceedings of the Second International Conference on Bipolar Disonler. 1997:26. Abstract.
49. Frye, MA, Ketter, TA, Kimbrell, TA. et al.Gabapentin and lamotrigine monotherapy in mood disorder. Syllabus and Proceedings Summary of the 150th American Psychiatric Association Meeting, May 17-22, 1997. Abstract No. 33C.
50. Messenheimer, JA. Lamotrigine. Epilepsia. 1995;36(suppl 2):S87S94.
51. Sachs, B, Ronnau, AC, von Schmiedeberg, S, Ruzicka, T, Gleiehmann, E, Schuppe, HC. Lamotrigine-induced Stevens-Johnson syndrome: demonstration of specific lymphocyte reactivity in vitro. Dermatology. 1997;195:6064.
52. Sterker, M, Berrouschot, J, Schneider, D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther. l995;33:595597.
53. Kocsis, JD, Mattson, RH. GABA levels in the brain: a target for new antiepileptic drugs. The Neuroscientist. 1996;2:326334.
54. Young, LT, Robb, JC, Patelis-Siotis, I, MacDonald, C, Joffe, RT. Acute treatment of bipolar depression with gabapentin. Biol Psychiatry. 1997;42:851853.
55. Dimond, KR, Pande, AC, Lamoreaux, L, Pierce, MW. Effect of gabapentin (Neurotonin) on mood and well-being in patienls with epilepsy. Prog Neuropsychopharmacol Biol Psychiatry. 1996;20:407417.
56. Marcotte, DB, Fogleman, L, Wolfe, N, et al.Gabapentin: an effective therapy for patients with bipolar affective disorder. APA New Research Program and Abstracts. 1997;138. Abstract NR261.
57. Joffe, RT, Singer, W, Levitt, AJ, MacDonald, C. A placebo-controlled comparison of lithium and triiodothyronine augmentation of triryclic antidepressanls in unipolar refractory depression. Arch Gen Psychiatry. 1993;50:387393.
58. Cooke, RG, Joffe, RT, Levitt, AJ. T3 augmentation of antidepressant treatment in T4-replaced thyroid palienls. J Clin Psychiatry. 1992;53:1618.
59. Stancer, HC, Persad, E. Treatment of intractable rapid-cycling manic-depressive disorder with levothyroxine. Arch Gen Psychiatry. 1982;39:311312.
60. Whyhrow, PC. The therapeutic use of triiodothyronine and high dose thyroxine in psychiatric disorder. Acta Med Austriaca. 1994;21:4752.
61. Baumgartner, A, Bauer, M, Hellweg, R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmacol. 1994;10:183189.
62. Frye, MA, Denicoff, KD, Luckenbaugh, DA, et al.Thyroid potentiation in affective illness. APA New Research Program and Abstracts. 1997. Abstract NR425.
63. Bauer, MS, Whybrow, PC. Rapid cycling bipolar affective disorder. II: treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry. 1990;47:435440.
64. Bauer, M, Hellweg, R, Baumgartner, A. Adjunctive treatment with high-dose thyroxine in refractory depression. APA New Research Program and Abstracts. 1996;156. Abstract NR330.
65. Perucca, E. A pharmacological and clinical review on topiramate, a new antiepileptic drug. Pharmacol Res. 1997;35:241256.
66. Shorvon, SD. Safely of topiramate: adverse events and relationships to dosing. Epilepsia, 1996;37(supp] 2):S18S22.
67. Ozaki, N, Chuang, DM. Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rad brain. J Neurochem. 1997;69:23362344.
68. Chen, G, Yuan, P, Hawver, DB, Potter, WZ, Manji, HK. Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology. 1997;16:238245.
69. Duman, RS, Heninger, GR, Nestler, EJ. A molecular and cellular theory of depression. Arch Gen Psychiatry. 1997;54:597606.
70. Smith, MA, Makino, S, Allemus, M, et al. Stress and antidepressants differentially regulate neurotrophin 3 mRNA expression in ihe locus coeruleus. Proc Natl Acad Sci USA. 1995;92:87888792.
71. Siuciak, JA, Lewis, DR, Wiegand, SJ, Lindsay, RM. Antidepressant-like effect of brain-derived neurotrophic factor (BDNF). Pharmacol Biochem Rehar. 1997;56:131137.
72. Baastrup, PC, Schou, M. Lithium as a prophylactic agent: its effect against recurrent depressions and manic-depressive psychosis. Arch Gen Psychiatry. 1967;16:162172.
73. Suppes, T, Baldessarini, RJ, Faedda, GL, Tohen, M. Risk of recurrence following discontinuation of lithium treatment in bipolar disorder. Arch Gen Psychiatry. 1991;48:10821088.
74. Faedda, GL, Tondo, L, Baldessarini, RJ, Suppes, T, Tohen, M. Outcome after rapid vs gradual discontinuation of lithium treatment in bipolar disorders. Arch Gen Psychiatry: 1993;50:448455.
75. Post, RM, Leverich, GS, Altshuler, L, Mikalauskas, K. Lithium discontinuation-induced refractoriness: preliminary observations. Am J Psychiatry. 1992;149:17271729.
76. Brodie, MJ, Yuen, AW. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997;26:423432.
77. Ketter, TA, Kimbrell, TA, George, MS, et al.Baseline hypermetabolism may predict carbamazepine response, and hypometabolism nimodipine response in mood disorders. Abstracts of the XXth CINP Congress. 1996:10.
78. Frye, MA, Pazzaglia, PJ, Luckenbaugh, D, et al.Baseline CSF somatostatin predictive of nimodipine treatment response. Biol Psychiatry. 1997;41:335. Abstract.
79. George, MS, Wassermann, EM, Williams, WA, et al. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. NeuroReport. 1995;6:18531856.
80. George, MS, Wassermann, EM, Kimbrell, TA, et al. Mood improvement following daily left prefrontal repetitive transcranial magnetic stimulation in patients with depression: a placebo-controlled crossover trial. Am J Psychiatry. 1997;154:17521756.
81. Pascual-Leone, A, Rubio, B, Pallardo, F, Catala, MD. Rapidrale transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression, Lancet 1996;348:233237.

The Role of Complex Combination Therapy in the Treatment of Refractory Bipolar Illness

  • Robert M. Post (a1), Mark A. Frye (a1), Gabriele S. Leverich (a1) and Kirk D. Denicoff (a1)

Metrics

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed